SUMANT SAINI

Dr. SUMANT SAINI

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Drug Discovery Today
Verified
Journal Article
Closed access
SBSarwar Beg
Sarwar Beg
MRMahfoozur Rahman
Mahfoozur Rahman
AJAtul Jain
Atul Jain
SSSUMANT SAINI
SUMANT SAINI
PMPatrick Midoux
Patrick Midoux
SASohail Akhter
Sohail Akhter

1 September 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SSSUMANT SAINI
SUMANT SAINI
TSTeenu Sharma
Teenu Sharma
AJAtul Jain
Atul Jain
HKHarmanjot Kaur
Harmanjot Kaur
OKO.P. Katare
O.P. Katare
BSBhupinder Singh
Bhupinder Singh

1 September 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SLShikha Lohan
Shikha Lohan
KRKaisar Raza
Kaisar Raza
SMS.K. Mehta
S.K. Mehta
GBGurjit Kaur Bhatti
Gurjit Kaur Bhatti
SSSUMANT SAINI
SUMANT SAINI
BSBhupinder Singh
Bhupinder Singh

1 June 2016 in Powder Technology
Verified
Journal Article
Closed access
SBSarwar Beg
Sarwar Beg
OKO.P. Katare
O.P. Katare
SSSUMANT SAINI
SUMANT SAINI
BGBabita Garg
Babita Garg
RKRajneet Kaur Khurana
Rajneet Kaur Khurana
BSBhupinder Singh
Bhupinder Singh

1 January 2017 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MRMahfoozur Rahman
Mahfoozur Rahman
SBSarwar Beg
Sarwar Beg
AVAmita Verma
Amita Verma
FAFahad A Al Abbasi
Fahad A Al Abbasi
FAFiroz Anwar
Firoz Anwar
VKVikas Kumar
Vikas Kumar

8 November 2017 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SBSarwar Beg
Sarwar Beg
SSSUMANT SAINI
SUMANT SAINI
SBSHANTANU BANDOPADHYAY
SHANTANU BANDOPADHYAY
OKO. P. Katare
O. P. Katare
BSBhupinder Singh
Bhupinder Singh
This research work entails quality by design (QbD)-based systematic development of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil (OLM) with improved biopharmaceutical attributes. Quality target product profile (QTPP) was defined and critical quality attributes (CQAs) were earmarked. Solubility of drug was performed in various lipids for screening of them. NLCs were prepared by hot-microemulsion method using solid lipids, liquid lipids and surfactants with maximal solubility. Failure mode and effect analysis (FMEA) was carried out for identifying high risk formulation and process parameters. Further, principal component analysis (PCA) was applied on high risk parameters for evaluating the effect of type and concentration of lipids and surfactants on CQAs. Further, systematic optimization of critical material attributes (CMAs) was carried out using face centered cubic design and optimized formulation was identified in the design space. FMEA and PCA suggested suitability of stearic acid, oleic acid and Tween 80 as the CMAs for NLCs. Response surface optimization helped in identifying the optimized NLC formulation with particle size ∼250 nm, zeta potential 75%, in vitro drug release >80% within 6 h. Release kinetic modeling indicated drug release through Fickian-diffusion mechanism. Overall, these studies indicated successful development of NLCs using multivariate statistical approaches for improved product and process understanding.